A liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor, a new study shows.
This kind of biopsy can detect lingering disease and could serve as a guide for deciding whether a patient should undergo further treatments due to some tumor cells evading an initial attempt to eradicate the cancer.
The findings appear in the
While the Food and Drug Administration has approved a few liquid biopsies, mostly for lung, breast, ovarian, and prostate cancers, it has not approved any for colorectal cancer.
Blood and urine samples identify disease that lingers after initial therapy
Researchers at Washington University School of Medicine in St. Louis have developed a liquid biopsy examining blood or urine that could help guide treatment for colorectal cancer patients. Nadja Pejovic, a visiting medical student and co-first author of a study on the liquid biopsy, works with a sample in the lab of Aadel Chaudhuri, MD, the study s senior author. (Photo: Peter Harris)
February 12, 2021 SHARE
A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor. Such a biopsy can detect lingering disease and could serve as a guide for deciding whether a patient should undergo further treatments due to some tumor cells evading an initial attempt to eradicate the cancer.
Liquid Biopsy Marks The Progression Of Colorectal Cancer by Karishma Abhishek on February 16, 2021 at 10:42 AM
Liquid biopsy assessing the blood or urine samples may help monitor the effectiveness of cancer therapy for the initial phase of colorectal cancer metastasis (oligometastatic) as per a study from Washington University School of Medicine in St. Louis, published in the Journal of Clinical Oncology Precision Oncology, a journal of the American Society of Clinical Oncology. Oligometastatic colorectal cancer requires initial chemotherapy to shrink and remove the remains of the primary tumor before having surgery. Food and Drug Administration (FDA) has approved a few liquid biopsies for lung, breast, ovarian, and prostate cancers, but none has been approved for colorectal cancer.
A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor.
A liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumour, a new study suggests.Such a biopsy can detect lingering disease and could serve .